Search research articles
Contact Us
Filters
Showing results (11-20 of 341) with videos related to
Page
of 35
Sort By:
Cancer
|
December 4, 2004
Richter syndrome: biology, incidence, and therapeutic strategies
Apostolia-Maria Tsimberidou, Michael J Keating
Leukemia & Lymphoma
|
September 13, 2012
Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?
Constantine S Tam, Michael J Keating
Seminars in Oncology
|
February 1, 2017
Emerging information on the use of rituximab in chronic lymphocytic leukemia
Michael J Keating, Susan O'Brien, Maher Albitar
Expert Review of Anticancer Therapy
|
October 6, 2006
Monoclonal antibodies in chronic lymphocytic leukemia
Alessandra Ferrajoli, Stefan Faderl, Michael J Keating
Seminars in Oncology
|
February 14, 2002
Emerging information on the use of rituximab in chronic lymphocytic leukemia
Michael J Keating, Susan O'Brien, Maher Albitar
Current Hematologic Malignancy Reports
|
April 29, 2010
New aspects of the treatment of chronic lymphocytic leukemia
Stefan Faderl, William Wierda, Michael J Keating
Best Practice & Research. Clinical Haematology
|
September 26, 2006
Monoclonal antibody combinations in CLL: evolving strategies
Stefan Faderl, Susan O'Brien, Michael J Keating
Critical Reviews in Oncology/Hematology
|
August 15, 2013
Targeting inflammatory pathways in chronic lymphocytic leukemia
Uri Rozovski, Michael J Keating, Zeev Estrov
Acta Haematologica
|
August 17, 2018
Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?
Uri Rozovski, Michael J Keating, Zeev Estrov
Molecular Cancer Therapeutics
|
December 7, 2002
UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes
Takahiro Yamauchi, Michael J Keating, William Plunkett
Page
of 35
Search research articles
Search
Showing results (11-20 of 341) with videos related to
Sort By:
Page
of 35
Cancer
|
December 4, 2004
Richter syndrome: biology, incidence, and therapeutic strategies
Apostolia-Maria Tsimberidou, Michael J Keating
Leukemia & Lymphoma
|
September 13, 2012
Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?
Constantine S Tam, Michael J Keating
Seminars in Oncology
|
February 1, 2017
Emerging information on the use of rituximab in chronic lymphocytic leukemia
Michael J Keating, Susan O'Brien, Maher Albitar
Expert Review of Anticancer Therapy
|
October 6, 2006
Monoclonal antibodies in chronic lymphocytic leukemia
Alessandra Ferrajoli, Stefan Faderl, Michael J Keating
Seminars in Oncology
|
February 14, 2002
Emerging information on the use of rituximab in chronic lymphocytic leukemia
Michael J Keating, Susan O'Brien, Maher Albitar
Current Hematologic Malignancy Reports
|
April 29, 2010
New aspects of the treatment of chronic lymphocytic leukemia
Stefan Faderl, William Wierda, Michael J Keating
Best Practice & Research. Clinical Haematology
|
September 26, 2006
Monoclonal antibody combinations in CLL: evolving strategies
Stefan Faderl, Susan O'Brien, Michael J Keating
Critical Reviews in Oncology/Hematology
|
August 15, 2013
Targeting inflammatory pathways in chronic lymphocytic leukemia
Uri Rozovski, Michael J Keating, Zeev Estrov
Acta Haematologica
|
August 17, 2018
Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?
Uri Rozovski, Michael J Keating, Zeev Estrov
Molecular Cancer Therapeutics
|
December 7, 2002
UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes
Takahiro Yamauchi, Michael J Keating, William Plunkett
Page
of 35